Risk of Mortality and Heart Failure with Myosin Inhibition Among Hypertrophic Cardiomyopathy Patients

被引：0
|
作者：
Patel, Nirav
Shetty, Naman
Gaonkar, Mokshad
Divekar, Girija
Vekariya, Nehal
Peng, Li
Arora, Garima
Arora, Pankaj
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4136203
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4136203
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Heart failure in hypertrophic cardiomyopathy: how to predict?
    Silverio Antonio, P.
    Rigueira, J.
    Rodrigues, T.
    Placido, R.
    Cunha, N.
    Aguiar-Ricardo, I.
    Santos, R.
    Nunes-Ferreira, A.
    Pereira, S.
    Morais, P. S.
    Campos, P.
    Pinto, F. J.
    Almeida, A. G.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 396 - 396
  • [32] Predictors of heart failure hospitalizations in hypertrophic cardiomyopathy
    Cecconi, A.
    Viliani, D.
    Pozo, E.
    Agudo-Quilez, P.
    Gonzalez-Bartol, E.
    Rojas-Gonzalez, A.
    Diego-Nieto, G.
    Garcia-Moreno, L. M.
    Dominguez-Arganda, L.
    Hernandez, S.
    Olivera, M. J.
    Caballero, P.
    Jimenez-Borreguero, J.
    Alfonso, F.
    EUROPEAN HEART JOURNAL, 2017, 38 : 406 - 406
  • [33] Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score
    Laenens, Dorien
    Zegkos, Thomas
    Kamperidis, Vasileios
    Wong, Raymond C. C.
    Li, Tony Yi-Wei
    Sia, Ching-Hui
    Kong, William K. F.
    Efthimiadis, Georgios
    Poh, Kian Keong
    Ziakas, Antonios
    Bax, Jeroen J.
    Marsan, Nina Ajmone
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (10) : 2173 - 2182
  • [34] Assessment of clinical risk factors for all-cause mortality among hypertrophic cardiomyopathy patients with ICDs
    Mielczarek, S.
    Syska, P.
    Lewandowski, M.
    Przybylski, A.
    Sterlinski, M.
    Maciag, A.
    Zajac, D.
    Kowalik, I.
    Pytkowski, M.
    Szwed, H.
    EUROPEAN HEART JOURNAL, 2019, 40 : 585 - 585
  • [35] Coexistence of mitochondrial DNA and β myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure
    Arbustini, E
    Fasani, R
    Morbini, P
    Diegoli, M
    Grasso, M
    Dal Bello, B
    Marangoni, E
    Banfi, P
    Banchieri, N
    Bellini, O
    Comi, G
    Narula, J
    Campana, C
    Gavazzi, A
    Danesino, C
    Viganó, M
    HEART, 1998, 80 (06) : 548 - 558
  • [36] The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy
    Haraf, Rebecca
    Habib, Hany
    Masri, Ahmad
    CANADIAN JOURNAL OF CARDIOLOGY, 2024, 40 (05) : 800 - 819
  • [37] Difference in the severity of left ventricular remodeling at the onset of heart failure and in the prognosis after heart failure in patients with hypertrophic cardiomyopathy and dilated cardiomyopathy
    Hamada, M
    Inaba, S
    Aono, J
    Ikeda, S
    Watanabe, K
    Shigematsu, Y
    CIRCULATION, 2006, 113 (08) : E329 - E329
  • [38] Progression of Myocardial Dysfunction in Hypertrophic Cardiomyopathy Patients: Association With Heart Failure Outcomes
    Hiemstra, Yasmine L.
    Debonnaire, Philippe
    van Wijngaarden, Suzanne E.
    Bootsma, Marianne
    Schalij, Martin J.
    Bax, Jeroen J.
    Delgado, Victoria
    Marsan, Nina A.
    CIRCULATION, 2016, 134
  • [39] The role of endothelin system in the formation of chronic heart failure in patients with hypertrophic cardiomyopathy
    Shakaryants, G. A.
    Kozhevnikova, M. V.
    Kaplunova, V. Y. U.
    Privalova, E. V.
    Chekneva, I. S.
    Khabarova, N. V.
    Belenkov, Y. U. N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 60 - 60
  • [40] Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure
    Ercan Varol
    Mehmet Ozaydin
    Ahmet Altinbas
    Suleyman M. Aslan
    Abdullah Dogan
    Ozkan Dede
    Heart and Vessels, 2007, 22 : 30 - 33
12345